What question did this study set out to answer?

This analysis examines how differing intellectual property rights and regulatory approaches affect access to medicines and pharmaceutical spending across the U.S., EU, and India.

July 27, 2026Journal of Generic Medicines The Business Journal for the Generic Medicines Sector

Divergent philosophies in pharmaceutical intellectual property: A comparative analysis of regulatory, pricing, and litigation regimes in the United States, European union, and pro-public health jurisdictions

View Full Paper

Ask AI

Bookmark

This analysis examines how differing intellectual property rights and regulatory approaches affect access to medicines and pharmaceutical spending across the U.S., EU, and India.
Comparative analysis of pharmaceutical IPR strategies in the U.S., EU, and India.
Evaluation of regulatory processes such as Hatch-Waxman and Multi-Track Authorization.
Assessment of pricing mechanisms and their effects on accessibility and affordability.
The U.S. model emphasizes strong patent protection, leading to high drug prices and a competitive generic market.
The EU adopts a balanced approach with national government interventions in pricing, yielding moderate drug costs.
India's legal framework supports affordable generics through anti-evergreening laws and compulsory licensing, enhancing access to medicines.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative analysis explores pharmaceutical IPR strategies' impact on access to medicines in key regions, suggesting broad implications for global health.

Cite This Study

Raviraj Kadam (2026) studied this question.

synapsesocial.com/papers/6a67008840bca442e0d4a33b https://doi.org/10.1177/17411343261471713

View Full Paper

Ask AI

Bookmark

Implication

Comparative analysis explores pharmaceutical IPR strategies' impact on access to medicines in key regions, suggesting broad implications for global health.

Divergent philosophies in pharmaceutical intellectual property: A comparative analysis of regulatory, pricing, and litigation regimes in the United States, European union, and pro-public health jurisdictions

Key Points

Discussion

Implication

Cite This Study

Divergent philosophies in pharmaceutical intellectual property: A comparative analysis of regulatory, pricing, and litigation regimes in the United States, European union, and pro-public health jurisdictions

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider